In this episode of "The Top Line," we talk with Fierce’s Max Bayer and Angus Liu about the most important news coming from this year's annual BIO conference. We also cover a COVID lawsuit, an FDA-approved app, and the rest of the week's headlines. 

To learn more about the topics in this episode:

• ASCO: After lung cancer fails, Roche's faith in TIGIT rewarded as tiragolumab shows signs of life in liver cancer
• Merck ends last Keytruda trial in aggressive prostate cancer campaign, takes separate hit in lung cancer
• Roche, with HER2 franchise under pressure, pays $70M for breast cancer brain metastases prospect
• Takeda pledges up to $1.13B for rights to Hutchmed's cancer drug fruquintinib outside of China
• BIO: Moderna to test mpox vaccine in humans this summer
• BIO: Jazz is auditioning new bandmates in an M&A market ripe with talent
• BioNTech to defend itself against COVID-19 vaccine injury claim in Germany
• Salvation or 'death warrant'? Erytech's war with activist investor rumbles on as merger vote nears
• RSV vaccine awareness low among older adults, but majority would ask their doc about new shots: survey
• Huma nabs FDA nod for AI-backed disease management platform
• Medtronic warns cardioversion can fry some Vanta neurostimulators

"The Top Line" is produced by senior podcast producer Teresa Carey. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.